RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y

Key Takeaways Recursion Pharmaceuticals reported a Q3 loss of $0.36 per share, narrower than expected.Q3 revenues fell sharply to $5.2 million, missing estimates due to year-ago quarter Roche milestone timing.RXRX is advancing REC-4881, REC-1245, and other early-stage assets with data expected through 2027.Recursion Pharmaceuticals (RXRX) reported a loss of 36 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss of 34 ...